1 | 202129 dubna 2021 0 | | | | | | | 4 | 0.55% |
2 | ncbi reference sequence refseq | | | | | | | 4 | 0.55% |
3 | u metastazujícího karcinomu prostaty | | | | | | | 3 | 0.42% |
4 | mia 20 dubna 2021 | | | | | | | 3 | 0.42% |
5 | abirateron u metastazujícího karcinomu | | | | | | | 3 | 0.42% |
6 | mia 29 dubna 202129 | | | | | | | 2 | 0.28% |
7 | května 202129 dubna 2021 | | | | | | | 2 | 0.28% |
8 | refseq aktualizace referenčních sekvencí | | | | | | | 2 | 0.28% |
9 | 15 16 17 18 | | | | | | | 2 | 0.28% |
10 | 20 dubna 202120 dubna | | | | | | | 2 | 0.28% |
11 | metastazujícího karcinomu prostaty ncbi | | | | | | | 2 | 0.28% |
12 | sequence refseq dbsnp databáze | | | | | | | 2 | 0.28% |
13 | dubna 202120 dubna 2021 | | | | | | | 2 | 0.28% |
14 | nejnovĚjŠÍ pŘÍspĚvky integrované polovodičové | | | | | | | 2 | 0.28% |
15 | refseq dbsnp databáze ncbi | | | | | | | 2 | 0.28% |
16 | reference sequence refseq database | | | | | | | 2 | 0.28% |
17 | června 202129 dubna 2021 | | | | | | | 2 | 0.28% |
18 | immune polyclonals realtime tissues | | | | | | | 2 | 0.28% |
19 | umožňující refseq aktualizace referenčních | | | | | | | 2 | 0.28% |
20 | mia 20 dubna 202120 | | | | | | | 2 | 0.28% |
21 | 29 dubna 202129 dubna | | | | | | | 2 | 0.28% |
22 | dubna 202129 dubna 2021 | | | | | | | 2 | 0.28% |
23 | dubna 2021 0 in | | | | | | | 2 | 0.28% |
24 | the amyloid precursor protein | | | | | | | 2 | 0.28% |
25 | 20 dubna 2021 0 | | | | | | | 2 | 0.28% |
26 | dbsnp databáze ncbi genetických | | | | | | | 2 | 0.28% |
27 | databáze ncbi genetických variací | | | | | | | 2 | 0.28% |
28 | more antiace2 antibody mia | | | | | | | 1 | 0.14% |
29 | enzyme 2 ace2 plays | | | | | | | 1 | 0.14% |
30 | renal and myocardial physiology | | | | | | | 1 | 0.14% |
31 | central role in vascular | | | | | | | 1 | 0.14% |
32 | a central role in | | | | | | | 1 | 0.14% |
33 | plays a central role | | | | | | | 1 | 0.14% |
34 | ace2 plays a central | | | | | | | 1 | 0.14% |
35 | 2 ace2 plays a | | | | | | | 1 | 0.14% |
36 | 0 angiotensinconverting enzyme 2 | | | | | | | 1 | 0.14% |
37 | angiotensinconverting enzyme 2 ace2 | | | | | | | 1 | 0.14% |
38 | antiace2 antibody mia 20 | | | | | | | 1 | 0.14% |
39 | 1999 had been extensively | | | | | | | 1 | 0.14% |
40 | 202120 dubna 2021 0 | | | | | | | 1 | 0.14% |